%0 Journal Article %A T., Song %A D.H., Lee %A Y.W., Jung %A B.S., Yun %A S.J., Seong %A C.H., Choi %A J.-W., Lee %A D.-S., Bae %A B.-G., Kim %D 2017 %T Supplementary Material for: Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis? %U https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Elevated_Preoperative_CA125_or_CA19-9_in_Borderline_Ovarian_Tumors_Could_It_Be_Suggestive_of_Advanced_Stage_or_a_Poor_Prognosis_/5057479 %R 10.6084/m9.figshare.5057479.v1 %2 https://karger.figshare.com/ndownloader/files/8560315 %K Borderline ovarian tumors %K Tumor marker %K CA125 %K CA19-9 %K Prognosis %X

Objectives: To investigate whether elevated levels of CA125 (≥35 U/mL) and CA19-9 (≥37 U/mL) suggest advanced-stage disease (defined as stage II or higher) or poor prognosis in patients with borderline ovarian tumors (BOTs). Study Design: We retrospectively identified 591 patients with BOTs. Multivariate logistic regressions and Cox proportional hazard regressions were used to determine the clinicopathologic factors associated with the presence of advanced-stage disease and the prognostic factors associated with recurrence-free survival. Results: CA125 was elevated more often in serous than in mucinous tumors (50.6 vs. 35.5%; p = 0.003), whereas CA19-9 was elevated more often in mucinous than serous tumors (33.6 vs. 15.3%; p = 0.001). An elevated CA125 level was independently associated with the presence of advanced-stage disease in serous (p = 0.005) and in mucinous BOTs (p = 0.015). However, preoperative elevation of CA19-9, unlike CA125, was not associated with the advanced-stage disease. Elevated preoperative CA125 level (p = 0.037) was an independent prognostic factor for recurrence-free survival in patients with serous BOTs. However, neither CA125 nor CA19-9 had prognostic significance in mucinous BOTs. Conclusions: Elevated preoperative CA125, unlike CA19-9, is a diagnostic and prognostic biomarker associated with the presence of advanced-stage disease and risk of relapse in patients with serous BOTs.

%I Karger Publishers